Following the philosophy of "Precise Products, Predictable Effects, Health Protection", Kexing Biopharm is devoted to promoting the R&D of quality biopharmaceutical products with improved clinical value, acting as the safeguard of human's health.
-
1989
Shenzhen Kexing Bioproducts Co., Ltd., was established as an industrial base for interferon production.
-
1996
"Recombinant Human Interferon α1b for Injection" (SINOGEN) was officially approved for production as Class I biological products.
-
1997
Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
-
1998
"Recombinant Human Erythropoietin Injection (CHO Cell)" (EPOSINO) was officially approved for production as Class II biological products.
-
2001
Recombinant Human Granulocyte Colony-stimulating Factor Injection (WHITE-C) was officially approved for production.
-
2002
Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CHANG LEKANG) was officially approved for production.
-
2009
The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).
-
2014
We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.
-
2017
Our technology center was ratified as the "Shandong Provincial Enterprise-level Technology Center"
-
2018
Our technology center was ratified as the "Jinan Protein Therapeutics Engineering Laboratory".
-
2019
We launched the slogan "Precise Products, Predictable Effects, Health Protection" and the new logo.
-
2019
The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).
Scan Code Consultation